Related Experiment Video
Updated: May 22, 2026
In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
Published on: July 19, 2024
Ezetimibe reduces fatty acid quantity in liver and decreased inflammatory cell infiltration and improved NASH in
Toshiyuki Oishi1, Shuji Terai, Shinya Kuwashiro
1Department of Gastroenterology & Hepatology, Yamaguchi University, Graduated School of Medicine, Minami Kogushi 1-1-1, Ube, Yamaguchi 755-8505, Japan.
Purpose:
We previously developed medaka non-alcoholic steatohepatitis (NASH) model. The model showed similar histology with human NASH so we analyzed the effect of drug using medaka NASH activity score (MNAS). In this study we analyzed the effect of ezetimibe, a small intestine cholesterol transporter inhibitor, on NASH.
Methods:
Medaka NASH model showed steatohepatits with infiltration of D-PAS positive inflammatory cell. In this study we induced medaka NASH and compared the effect of ezetimibe on medaka NASH by HFD.
Results:
As compared with the HFD group, ezetimibe reduced total cholesterol and triacyglycerol in the blood. But concerning with liver quantity of fatty acids in the liver were significantly decreased by ezetimibe. Genes related with fatty acid metabolism in liver was also decreased by ezetimibe administration. On histological observations of the liver, increases in the number of inflammatory cells and MNAS were inhibited. With this decrease of fatty acid in liver, medaka NASH was improved by ezetimibe.
Conclusion:
Ezetimibe was clarified as a useful drug to improve NASH.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management